AU4328399A - Nucleic acid-cobalamin complexes and their use in gene therapy - Google Patents

Nucleic acid-cobalamin complexes and their use in gene therapy

Info

Publication number
AU4328399A
AU4328399A AU43283/99A AU4328399A AU4328399A AU 4328399 A AU4328399 A AU 4328399A AU 43283/99 A AU43283/99 A AU 43283/99A AU 4328399 A AU4328399 A AU 4328399A AU 4328399 A AU4328399 A AU 4328399A
Authority
AU
Australia
Prior art keywords
nucleic acid
gene therapy
cobalamin
complexes
cobalamin complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU43283/99A
Inventor
Pamela K. Foreman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of AU4328399A publication Critical patent/AU4328399A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
AU43283/99A 1998-06-15 1999-06-02 Nucleic acid-cobalamin complexes and their use in gene therapy Abandoned AU4328399A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8929198P 1998-06-15 1998-06-15
US60089291 1998-06-15
PCT/US1999/012236 WO1999065529A1 (en) 1998-06-15 1999-06-02 Nucleic acid-cobalamin complexes and their use in gene therapy

Publications (1)

Publication Number Publication Date
AU4328399A true AU4328399A (en) 2000-01-05

Family

ID=22216811

Family Applications (1)

Application Number Title Priority Date Filing Date
AU43283/99A Abandoned AU4328399A (en) 1998-06-15 1999-06-02 Nucleic acid-cobalamin complexes and their use in gene therapy

Country Status (2)

Country Link
AU (1) AU4328399A (en)
WO (1) WO1999065529A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ071299A0 (en) * 1999-06-02 1999-06-24 Access Pharmaceuticals Australia Pty Limited Vitamin directed dual targeting therapy
US7591995B2 (en) 1999-10-15 2009-09-22 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
CN1301718A (en) * 1999-12-27 2001-07-04 上海博德基因开发有限公司 New polypeptide-cobalamin binding protein 10 and polynucleotide coding such polypeptide
ES2622399T3 (en) * 2001-03-16 2017-07-06 University Of Utah Research Foundation Fluorescent cobalamines and uses thereof
WO2003025139A2 (en) * 2001-09-17 2003-03-27 Mayo Foundation For Medical Education And Research Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ217821A (en) * 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
NZ242220A (en) * 1991-04-02 1994-04-27 Biotech Australia Pty Ltd Complex for oral delivery of a substance to the circulatory or lymphatic drainage system comprising microparticle coupled to at least one carrier, the substance being encapsulated by the microparticle
ATE239484T1 (en) * 1991-10-24 2003-05-15 Isis Pharmaceuticals Inc DERIVATIZED OLIGONUCLEOTIDES WITH IMPROVED ABSORPTION CAPACITY

Also Published As

Publication number Publication date
WO1999065529A1 (en) 1999-12-23

Similar Documents

Publication Publication Date Title
HUP9801216A3 (en) Dna molecules, preparation thereof and use thereof in gene therapy
AU7499198A (en) Gene expression profiles in normal and cancer cells
AU1606897A (en) Thymidine kinase variants, corresponding nucleic acid sequences and their use in gene therapy
AU3560399A (en) Tumor associated nucleic acids and uses therefor
AU1389597A (en) Novel dna glycosylases and their use
AU1922301A (en) Differential gene expression in cancer
AU5691699A (en) Human genes differentially expressed in colorectal cancer
AU8536998A (en) Regulatory sequences involved in hypoxia regulated gene expression and uses thereof
AU5918098A (en) Non-immunogenic prodrugs and selectable markers for use in gene therapy
HUP0104825A3 (en) Genes and proteins, and their use
IL136826A0 (en) Essential bacterial genes and their use
AU1520499A (en) Essential fungal genes and their use
AU1598599A (en) Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases
AU2238499A (en) Androgen-metabolic gene mutations and prostate cancer risk
AU4328399A (en) Nucleic acid-cobalamin complexes and their use in gene therapy
IL136005A0 (en) Essential bacterial genes and their use
AU2529799A (en) Benzofuran-4-carboxamides and their therapeutic use
IL112993A0 (en) Recombinant niruses, their preparation and their use in gene therapy
HUP0201022A2 (en) Outer surface proteins, their genes, and their use
AU6653698A (en) Use of the p-ten suppressor gene in diagnosis and treatment of cancer
AU5871898A (en) Microparticles and their use in cancer treatment
AU4860299A (en) (zap-3) tumor associated genes and their uses
AU1926699A (en) Cathepsin dc proteins, dna encoding the proteins, and their use in human cancer prognosis
AU3349997A (en) Reg gene expression in cancer tissue
AU6149600A (en) Novel vector complexes and their use in gene therapy

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase